Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Former U.S. Navy Chief Petty Office Bree Kuhn gunned down her husband, Collin Turner, in the couple's Florida home while he ...

The study found that Sogroya was more effective than a daily growth hormone in children with NS2. The results of a sub-study on Turner syndrome are expected to be released later this year. Novo ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...